Severe acute respiratory syndrome coronavirus 2 that causes coronavirus disease 2019 (COVID-19) is changing at a rapid pace due to accumulated mutations in the viral genetic code over time. As new variants of the virus continue to emerge and replace previous versions of the variants, therapeutics and vaccines are being constantly monitored and reviewed for their efficacy against the new strains. With the surge in new omicron sub-variants across the nation, U.S. Food and Drug Administration issued emergency use authorization to a new monoclonal antibody therapy called bebtelovimab replacing the previous sotrovimab that was effective against Omicron BA.1. The main objective of the paper is to review the current treatment options available to treat non-hospitalized mild-to-moderate COVID-19 caused by the new omicron sub-variants BA.2, BA.4, and BA.5. Scientists, pharmaceutical companies, and researchers have been proactive in conducting randomized, double-blinded, placebo-controlled clinical trials to test the safety and efficacy of therapeutics in managing COVID-19 in addition to testing the vaccine efficacy against new strains. The paper focuses on reviewing the results of these randomized controlled trials. The oral antiviral options paxlovid and molnupiravir, and intravenous (IV) bebtelovimab continue to show their efficacy against the new sub-variants BA.4 and BA.5. It is important for everyone to stay well-informed of the new treatment options and only opt for those medications that are currently authorized for use in treating mild-to-moderate COVID-19.